Biotech Values

[DewDiligence]

Severin Schwan, chief executive of Roche, Novartis’s crosstown rival, argued last month in an interview with the Financial Times: “A lot of people call it diversification. I call it giving up.”

Under the circumstances—NVS is firing on all cyclinders while Roche has encountered a few speed bumps—Schwan’s comments come across as sour grapes, IMO.